Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies.

van Meer S, de Man RA, Siersema PD, van Erpecum KJ.

World J Gastroenterol. 2013 Oct 28;19(40):6744-56. doi: 10.3748/wjg.v19.i40.6744. Review.

2.

Status quo of chronic liver diseases, including hepatocellular carcinoma, in Mongolia.

Jazag A, Puntsagdulam N, Chinburen J.

Korean J Intern Med. 2012 Jun;27(2):121-7. doi: 10.3904/kjim.2012.27.2.121. Epub 2012 May 31. Review.

3.

Hepatocellular carcinoma: diagnostics and screening.

Patel M, Shariff MI, Ladep NG, Thillainayagam AV, Thomas HC, Khan SA, Taylor-Robinson SD.

J Eval Clin Pract. 2012 Apr;18(2):335-42. doi: 10.1111/j.1365-2753.2010.01599.x. Epub 2010 Nov 30. Review.

PMID:
21114800
4.

Present and future possibilities for early diagnosis of hepatocellular carcinoma.

Stefaniuk P, Cianciara J, Wiercinska-Drapalo A.

World J Gastroenterol. 2010 Jan 28;16(4):418-24. Review.

5.

AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.

Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H.

BMC Cancer. 2008 Jul 18;8:200. doi: 10.1186/1471-2407-8-200.

6.

Surveillance for hepatocellular carcinoma: how can we do better?

Hassett M, Yopp AC, Singal AG.

Am J Med Sci. 2013 Oct;346(4):308-13. doi: 10.1097/MAJ.0b013e31828318ff.

PMID:
23426089
7.

[Guideline compliant diagnostics of hepatocellular carcinoma].

Plentz RR, Boozari B, Malek NP.

Radiologe. 2014 Jul;54(7):660-3. doi: 10.1007/s00117-014-2651-5. German.

PMID:
24981446
8.

[The diagnostic approach to hepatocellular carcinoma].

Schacherer D, Schoelmerich J, Zuber-Jerger I.

Z Gastroenterol. 2007 Oct;45(10):1067-74. Review. German.

PMID:
17924305
9.

A 70-year-old woman with 10 years of markedly elevated alpha-fetoprotein measurements.

Hsu SX, Siegel AB, Berk PD.

Semin Liver Dis. 2010 Feb;30(1):99-106. doi: 10.1055/s-0030-1247136. Epub 2010 Feb 19.

PMID:
20175037
10.

Hepatocellular carcinoma tumour markers: current role and expectations.

Rich N, Singal AG.

Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):843-53. doi: 10.1016/j.bpg.2014.07.018. Epub 2014 Aug 22. Review.

PMID:
25260312
11.

Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.

Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ.

World J Gastroenterol. 2013 Jan 21;19(3):339-46. doi: 10.3748/wjg.v19.i3.339.

12.

Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.

Waidmann O, Köberle V, Bettinger D, Trojan J, Zeuzem S, Schultheiß M, Kronenberger B, Piiper A.

J Hepatol. 2013 Oct;59(4):769-79. doi: 10.1016/j.jhep.2013.06.008. Epub 2013 Jun 17.

PMID:
23792028
13.

Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma.

Nomura F, Sogawa K, Noda K, Seimiya M, Matsushita K, Miura T, Tomonaga T, Yoshitomi H, Imazeki F, Takizawa H, Mogushi K, Miyazaki M, Yokosuka O.

Biochem Biophys Res Commun. 2012 May 18;421(4):837-43. doi: 10.1016/j.bbrc.2012.04.099. Epub 2012 Apr 25.

PMID:
22554520
14.

Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.

Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB.

Hepatology. 2010 Jul;52(1):132-41. doi: 10.1002/hep.23615.

15.

Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8. doi: 10.1111/j.1440-1746.2008.05395.x. Epub 2008 Apr 19.

PMID:
18422961
16.

Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in patients with chronic liver disease.

Hanaoka T, Sato S, Tobita H, Miyake T, Ishihara S, Akagi S, Amano Y, Kinoshita Y.

J Gastroenterol Hepatol. 2011 Apr;26(4):739-44. doi: 10.1111/j.1440-1746.2010.06585.x.

PMID:
21083609
17.

Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.

Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD; Italian Liver Cancer (ITA.LI.CA) Group.

J Hepatol. 2012 May;56(5):1089-96. doi: 10.1016/j.jhep.2011.11.022. Epub 2012 Jan 13.

PMID:
22245900
18.

Serum alpha-fetoprotein may have a significant role in the surveillance of hepatocellular carcinoma in hepatitis B endemic areas.

Sinn DH, Yi J, Choi MS, Kim YJ, Gwak GY, Lee JH, Koh KC, Paik SW, Yoo BC.

Hepatogastroenterology. 2015 Mar-Apr;62(138):327-32.

PMID:
25916058
19.

Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region.

Amarapurkar D, Han KH, Chan HL, Ueno Y; Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma.

J Gastroenterol Hepatol. 2009 Jun;24(6):955-61. doi: 10.1111/j.1440-1746.2009.05805.x. Epub 2009 Mar 11.

PMID:
19383082
20.

Viral hepatitis and hepatocellular carcinoma.

Marrero CR, Marrero JA.

Arch Med Res. 2007 Aug;38(6):612-20. Review.

PMID:
17613352
Items per page

Supplemental Content

Write to the Help Desk